The company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...

In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...

Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...

A cancer vaccine generated using the cells left over after tumour removal surgery could help to keep patients from ...

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...